Ikarian Capital, LLC Ovid Therapeutics Inc. Transaction History

Ikarian Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.69 - $3.31 $1.2 Million - $2.36 Million	-711,541 Reduced 96.37%	26,831 $59,000
Q1 2022 May 13, 2022	BUY	$2.65 - $3.49 $88,218 - $116,182	33,290 Added 4.72%	738,372 $2.32 Million
Q4 2021 Feb 14, 2022	SELL	$3.13 - $3.73 $1.25 Million - $1.49 Million	-400,000 Reduced 36.2%	705,082 $2.26 Million
Q3 2021 Nov 15, 2021	SELL	$3.31 - $4.04 $65,504 - $79,951	-19,790 Reduced 1.76%	1,105,082 $3.72 Million
Q1 2021 May 17, 2021	BUY	$2.42 - $4.47 $2.72 Million - $5.03 Million	1,124,872 New	1,124,872 $4.52 Million
Q2 2020 Aug 14, 2020	SELL	$2.67 - $7.91 $1.01 Million - $2.99 Million	-377,737 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$2.03 - $4.35 $56,306 - $120,655	27,737 Added 7.92%	377,737 $1.13 Million
Q4 2019 Jan 31, 2020	BUY	$2.08 - $5.06 $728,000 - $1.77 Million	350,000 New	350,000 $1.45 Million

39M

37.4K

500

Ticker OVID
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,419,400
Market Cap $74.6M
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.